Middle East & Africa Epilepsy Drugs Market Forecast to 2030
Middle East & Africa Epilepsy Drugs Market Forecast to 2030 – Regional Analysis – by Treatment (First Generation Anti-Epileptics, Second Generation Anti-Epileptics, and Third Generation Anti-Epileptics) and Distribution Channel (Hospital Pharmacy, Retail Pharmacy Stores, and Others)
$2,485 – $3,885
- Description
- Toplines
- Reasons for Buying
- Table of Contents
- List of Tables
- LIst of Figures
- List of Companies
- Reviews (0)
Description
Increasing Product Approvals Fuels Middle East & Africa Epilepsy Drugs Market
In recent years, there has been a notable increase in the approval of drugs to treat epilepsy, marking a significant step forward in addressing the challenges posed by severe seizures. Growing awareness of the need for effective therapeutic options and the dedicated efforts of researchers and pharmaceutical companies to develop innovative treatments are leading to the development and approval of these drugs.
Drug approvals and the diversity of new molecular entities (NMEs) upon which new drugs are based have been consistently growing over time. A notable growth in the number of drug approvals annually was also observed in the recent past. Thus, the acceptance of new drugs is rising and resulting in increasing approvals for the products.
Thus, the increasing number of regulatory approvals is becoming a trend in the epilepsy drug market worldwide.
Middle East & Africa Epilepsy Drugs Market Overview
The Middle East & Africa epilepsy drugs market is segmented into Saudi Arabia, South Africa, the UAE, and the Rest of Middle East & Africa. Epilepsy has several possible causes. The cause of epilepsy can only be identified in 32% of cases, while in the remaining cases, the cause of epilepsy is unidentifiable, i.e., idiomatic epilepsy. Common causes of epilepsy among South Africans include infectious disease, head trauma and alcohol abuse. South Africans have a relatively high mortality rate and high prevalence of epilepsy. According to the latest WHO data published in 2020, deaths due to epilepsy in South Africa reached 1,870, i.e., 0.41% of total deaths. Therefore, the increasing prevalence of epilepsy will upsurge the Middle East & Africa epilepsy drugs market.
Middle East & Africa Epilepsy Drugs Market Revenue and Forecast to 2030 (US$ Million)
Middle East & Africa Epilepsy Drugs Market Segmentation
The Middle East & Africa epilepsy drugs market is segmented into treatment, distribution channel, and country.
Based on treatment, the Middle East & Africa epilepsy drugs market is classified into first generation anti-epileptics, second generation anti-epileptics, and third generation anti-epileptics. The third-generation anti-epileptics segment held the largest share in 2022.
In terms of distribution channel, the Middle East & Africa epilepsy drugs market is categorized into hospital pharmacy, retail pharmacy stores, and others. The hospital pharmacy segment held the largest share in 2022.
Based on country, the Middle East & Africa epilepsy drugs market is segmented Saudi Arabia, South Africa, the UAE, and the Rest of Middle East & Africa. The Rest of Middle East & Africa dominated the Middle East & Africa epilepsy drugs market in 2022.
Abbott Laboratories, Alkem Laboratories Ltd, GSK Plc, Novartis AG, Pfizer Inc, Sanofi SA, and Teva Pharmaceutical Industries Ltd are some of the leading companies operating in the Middle East & Africa epilepsy drugs market.
Summary Info
| Industry: | |
|---|---|
| Pricing options: | |
| Geographical coverage: | |
| Year of Publication: |
According to the Research Team’ research, the Middle East & Africa epilepsy drugs market was valued at US$ 593.94 million in 2022 and is expected to reach US$ 741.26 million by 2030, registering a CAGR of 2.8% from 2022 to 2030. Growing prevalence of epilepsy and increasing number of elderly people are among the critical factors attributed to the Middle East & Africa epilepsy drugs market expansion.
Epilepsy is a neurological disorder characterized by recurrent seizures. According to the data published by the World Health Organization in February 2023, epilepsy accounts for a significant share of the global disease burden, affecting nearly 50 million people across the world. The projected proportion of the general population with active epilepsy (i.e., with the need for treatment or continuing seizures) at a given time is between 4 and 10 per 1,000 individuals. According to the same source (World Health Organization in February 2023), 5 million people are diagnosed with epilepsy every year worldwide. High-income countries are estimated to report epilepsy at a rate of 49 per 100,000 people annually. In low- and middle-income countries, this number can be as high as 139 per 100,000 individuals. This is likely due to the high risk of endemic conditions such as neurocysticercosis or malaria, birth-related injuries, and a high incidence of road traffic injuries. About 80% of individuals with epilepsy live in low- and middle-income countries. The data also reports that seizures can be controlled, and about 70% of individuals living with epilepsy could become seizure-free with appropriate use of antiseizure medicines. Antiepileptic drug therapy is the primary treatment for most patients with epilepsy. Seizure classification is a crucial element in designing the treatment plan, as some antiepileptic drugs have different effects against various seizure types. Thus, the rising prevalence and incidence of epilepsy worldwide are contributing to elevate the demand for epilepsy drugs.
On the contrary, recall of therapeutic products hampers the growth Middle East & Africa epilepsy drugs market.
Based on treatment, the Middle East & Africa epilepsy drugs market is classified into first generation anti-epileptics, second generation anti-epileptics, and third generation anti-epileptics. The third-generation anti-epileptics segment held 42.6% share of the Middle East & Africa epilepsy drugs market in 2022, amassing US$ 252.96 million. It is projected to garner US$ 326.81 million by 2030 to expand at 3.3% CAGR during 2022-2030.
Based distribution channel, the Middle East & Africa epilepsy drugs market is categorized into hospital pharmacy, retail pharmacy stores, and others. The hospital pharmacy segment held 51.2% share of the Middle East & Africa epilepsy drugs market in 2022, amassing US$ 303.87 million. It is projected to garner US$ 366.89 million by 2030 to expand at 2.4% CAGR during 2022-2030.
Based on country, the Middle East & Africa epilepsy drugs market is categorized into Saudi Arabia, South Africa, the UAE, and the Rest of Middle East & Africa. The Rest of Middle East & Africa held 27.8% share of Middle East & Africa epilepsy drugs market in 2022, amassing US$ 164.90 million. It is projected to garner US$ 192.98 million by 2030 to expand at 2.0% CAGR during 2022-2030.
Key players operating in the Middle East & Africa epilepsy drugs market are Abbott Laboratories, Alkem Laboratories Ltd, GSK Plc, Novartis AG, Pfizer Inc, Sanofi SA, and Teva Pharmaceutical Industries Ltd, among others.
In October 2023; Novartis completed the Sandoz’s spin-off through a dividend-in-kind distribution to holders of Novartis shares and American Depositary Receipts. Each holder received one Sandoz share for every five Novartis shares held at the close of business on October 3, 2023. The separation of Sandoz has led Novartis to complete its transformation, allowing it to focus as a medicines company.
o Highlights key business priorities in order to assist companies to realign their business strategies.
o The key findings and recommendations highlight crucial progressive industry trends in Middle East & Africa epilepsy drugs market, thereby allowing players across the value chain to develop effective long-term strategies.
o Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
o Scrutinize in-depth Middle East & Africa market trends and outlook coupled with the factors driving the market, as well as those hindering it.
o Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing, and distribution
TABLE OF CONTENTS
1. Introduction
1.1 the Research Team Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Insights
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Epilepsy Drugs Landscape
4.1 Overview
5. Middle East & Africa Epilepsy Drugs Market – Key Industry Dynamics
5.1 Market Drivers
5.1.1 Growing Prevalence of Epilepsy
5.1.2 Increasing Number of Elderly People
5.2 Market Restraints
5.2.1 Recall of Therapeutic Products
5.3 Market Opportunities
5.3.1 Several Epilepsy Drugs Nearing Patent Expiration
5.4 Future Trends
5.4.1 Increasing Product Approvals
5.5 Impact Analysis
6. Epilepsy Drugs Market – Middle East & Africa Market Analysis
6.1 Middle East & Africa Epilepsy Drugs Market Revenue (US$ Mn), 2022 – 2030
7. Middle East & Africa Epilepsy Drugs Market – Revenue and Forecast to 2030 – by Treatment
7.1 Overview
7.2 Middle East & Africa Epilepsy Drugs Market Revenue Share, by Treatment 2022 & 2030 (%)
7.3 First Generation Antiepileptics
7.3.1 Overview
7.3.2 First Generation Antiepileptics: Middle East & Africa Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
7.4 Second Generation Anti-epileptics
7.4.1 Overview
7.4.2 Second Generation Anti-epileptics: Middle East & Africa Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
7.5 Third Generation Anti-epileptics
7.5.1 Overview
7.5.2 Third Generation Anti-epileptics: Middle East & Africa Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
8. Middle East & Africa Epilepsy Drugs Market – Revenue and Forecast to 2030 – by Distribution Channel
8.1 Overview
8.2 Middle East & Africa Epilepsy Drugs Market Revenue Share, by Distribution Channel 2022 & 2030 (%)
8.3 Hospital Pharmacy
8.3.1 Overview
8.3.2 Hospital Pharmacy: Middle East & Africa Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
8.4 Retail Pharmacy Stores
8.4.1 Overview
8.4.2 Retail Pharmacy Stores: Middle East & Africa Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
8.5 Others
8.5.1 Overview
8.5.2 Others: Middle East & Africa Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9. Middle East & Africa Epilepsy Drugs Market – Revenue and Forecast to 2030 – Country Analysis
9.1 Middle East & Africa Epilepsy Drugs Market, by Key Country- Revenue (2022) (US$ Million)
9.1.1.1 South Africa: Middle East & Africa Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.1.1.1.1 Overview
9.1.1.1.2 South Africa: Middle East & Africa Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.1.1.1.3 South Africa: Middle East & Africa Epilepsy Drugs Market, by Treatment, 2020-2030 (US$ Million)
9.1.1.1.4 South Africa: Middle East & Africa Epilepsy Drugs Market, by Distribution Channel, 2020-2030 (US$ Million)
9.1.1.2 Saudi Arabia: Middle East & Africa Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.1.1.2.1 Overview
9.1.1.2.2 Saudi Arabia: Middle East & Africa Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.1.1.2.3 Saudi Arabia: Middle East & Africa Epilepsy Drugs Market, by Treatment, 2020-2030 (US$ Million)
9.1.1.2.4 Saudi Arabia: Middle East & Africa Epilepsy Drugs Market, by Distribution Channel, 2020-2030 (US$ Million)
9.1.1.3 UAE: Middle East & Africa Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.1.1.3.1 Overview
9.1.1.3.2 UAE: Middle East & Africa Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.1.1.3.3 UAE: Middle East & Africa Epilepsy Drugs Market, by Treatment, 2020-2030 (US$ Million)
9.1.1.3.4 UAE: Middle East & Africa Epilepsy Drugs Market, by Distribution Channel, 2020-2030 (US$ Million)
9.1.1.4 Rest of Middle East & Africa Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.1.1.4.1 Overview
9.1.1.4.2 Rest of Middle East & Africa Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.1.1.4.3 Rest of Middle East & Africa Epilepsy Drugs Market, by Treatment, 2020-2030 (US$ Million)
9.1.1.4.4 Rest of Middle East & Africa Epilepsy Drugs Market, by Distribution Channel, 2020-2030 (US$ Million)
10. Epilepsy Drugs Market-Industry Landscape
10.1 Overview
10.2 Growth Strategies in the Epilepsy Drugs Market
10.3 Inorganic Growth Strategies
10.3.1 Overview
10.4 Organic Growth Strategies
10.4.1 Overview
11. Company Profiles
11.1 Novartis AG
11.1.1 Key Facts
11.1.2 Business Description
11.1.3 Products and Services
11.1.4 Financial Overview
11.1.5 SWOT Analysis
11.1.6 Key Developments
11.2 Pfizer Inc
11.2.1 Key Facts
11.2.2 Business Description
11.2.3 Products and Services
11.2.4 Financial Overview
11.2.5 SWOT Analysis
11.2.6 Key Developments
11.3 GSK Plc
11.3.1 Key Facts
11.3.2 Business Description
11.3.3 Products and Services
11.3.4 Financial Overview
11.3.5 SWOT Analysis
11.3.6 Key Developments
11.4 Abbott Laboratories
11.4.1 Key Facts
11.4.2 Business Description
11.4.3 Products and Services
11.4.4 Financial Overview
11.4.5 SWOT Analysis
11.4.6 Key Developments
11.5 Sanofi SA
11.5.1 Key Facts
11.5.2 Business Description
11.5.3 Products and Services
11.5.4 Financial Overview
11.5.5 SWOT Analysis
11.5.6 Key Developments
11.6 Teva Pharmaceutical Industries Ltd
11.6.1 Key Facts
11.6.2 Business Description
11.6.3 Products and Services
11.6.4 Financial Overview
11.6.5 SWOT Analysis
11.6.6 Key Developments
11.7 Alkem Laboratories Ltd
11.7.1 Key Facts
11.7.2 Business Description
11.7.3 Products and Services
11.7.4 Financial Overview
11.7.5 SWOT Analysis
11.7.6 Key Developments
12. Appendix
12.1 About Us
12.2 Glossary of Terms
LIST OF TABLES
Table 1. Middle East & Africa Epilepsy Drugs Market Segmentation
Table 2. South Africa: Middle East & Africa Epilepsy Drugs Market, by Treatment – Revenue and Forecast to 2030 (US$ Million)
Table 3. South Africa: Middle East & Africa Epilepsy Drugs Market, by Distribution Channel – Revenue and Forecast to 2030 (US$ Million)
Table 4. Saudi Arabia: Middle East & Africa Epilepsy Drugs Market, by Treatment – Revenue and Forecast to 2030 (US$ Million)
Table 5. Saudi Arabia: Middle East & Africa Epilepsy Drugs Market, by Distribution Channel – Revenue and Forecast to 2030 (US$ Million)
Table 6. UAE: Middle East & Africa Epilepsy Drugs Market, by Treatment – Revenue and Forecast to 2030 (US$ Million)
Table 7. UAE: Middle East & Africa Epilepsy Drugs Market, by Distribution Channel – Revenue and Forecast to 2030 (US$ Million)
Table 8. Rest of Middle East & Africa Epilepsy Drugs Market, by Treatment – Revenue and Forecast to 2030 (US$ Million)
Table 9. Rest of Middle East & Africa Epilepsy Drugs Market, by Distribution Channel – Revenue and Forecast to 2030 (US$ Million)
Table 10. Recent Inorganic Growth Strategies in the Epilepsy Drugs Market
Table 11. Recent Organic Growth Strategies in the Epilepsy Drugs Market
Table 12. Glossary of Terms, Middle East & Africa Epilepsy Drugs Market
LIST OF FIGURES
Figure 1. Middle East & Africa Epilepsy Drugs Market Segmentation, By Country
Figure 2. Middle East & Africa Epilepsy Drugs Market: Key Industry Dynamics
Figure 3. Middle East & Africa Epilepsy Drugs Market: Impact Analysis of Drivers and Restraints
Figure 4. Middle East & Africa Epilepsy Drugs Market Revenue (US$ Mn), 2022 – 2030
Figure 5. Middle East & Africa Epilepsy Drugs Market Revenue Share, by Treatment 2022 & 2030 (%)
Figure 6. First Generation Anti-epileptics: Middle East & Africa Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
Figure 7. Second Generation Anti-epileptics: Middle East & Africa Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
Figure 8. Third Generation Anti-epileptics: Middle East & Africa Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
Figure 9. Middle East & Africa Epilepsy Drugs Market Revenue Share, by Distribution Channel 2022 & 2030 (%)
Figure 10. Hospital Pharmacy: Middle East & Africa Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
Figure 11. Retail Pharmacy Stores: Middle East & Africa Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
Figure 12. Others: Middle East & Africa Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
Figure 13. Middle East & Africa Epilepsy Drugs Market, by Key Country – Revenue (2022) (US$ Million)
Figure 14. Middle East & Africa Epilepsy Drugs Market, by Country, 2022 & 2030 (%)
Figure 15. South Africa: Middle East & Africa Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
Figure 16. Saudi Arabia: Middle East & Africa Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
Figure 17. UAE: Middle East & Africa Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
Figure 18. Rest of Middle East & Africa Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
Figure 19. Growth Strategies in the Epilepsy Drugs Market
The List of Companies – Middle East & Africa Epilepsy Drugs Market
1. Abbott Laboratories
2. Alkem Laboratories Ltd
3. GSK Plc
4. Novartis AG
5. Pfizer Inc
6. Sanofi SA
7. Teva Pharmaceutical Industries Ltd
You must be logged in to post a review.
Reviews
There are no reviews yet.